조갑진균증 치료와 재발에 관련된 인자들
Prognostic Factors for Cure and Recurrence of Onychomycosis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The cure of onychomycosis (OM) requires long-term oral antifungal treatment, and recurrences after successful treatment are relatively common (10~53%). Objective: We sought to determine the factors affecting the duration of treatment and identify risk factors for recurrence. Methods: We retrospectively reviewed successfully treated consecutive cases of onychomycosis between January 2006 and February 2010. We classified the patients into 7 groups: distal subungual onychomycosis (DSO) type I (~25% involved), type II (25~50%), type III (50~75%), type IV (75~100%), proximal subungual onychomycosis (PSO), superficial white onychomycosis (SWO), and candidal OM. The patients were treated with systemic agents including terbinafine, fluconazole and itraconazole. We analyzed the clinical data for factors affecting the duration of treatement and recurrence of onychomycosis. The factors included age, sex, subtype of onychomycosis, type of systemic antifungal agent as well as the existence of comorbidities. Results: A total of 227 patients were enrolled: their mean age was 56.9 years (range, 11~90); mean duration of treatment was 7.2 months (range, 1~24). The duration of treatment of DSO type I (6.2months) was shorter than that of DSO III (8.5 months) and IV (9.0 months). The other factors including age, sex, the existence of diabetes or vascular disease, and the type of systemic agents did not affect the duration of treatment. The recurrence rates after successful treatment were 12.5% in the patients with diabetes and 2.6% in the patients without diabetes (p = 0.026). There was no difference in recurrence rates of the patients with or without vascular diseases. Conclusion: The duration of treatment to cure OM increased with the degree of involvement of DSO. No other factors affected the treatment duration significantly. recurrence rate was significantly higher in patients with diabetes.
Abstract
Background: The cure of onychomycosis (OM) requires long-term oral antifungal treatment, and recurrences after successful treatment are relatively common (10~53%). Objective: We sought to determine the factors affecting the duration of treatment and identify risk factors for recurrence. Methods: We retrospectively reviewed successfully treated consecutive cases of onychomycosis between January 2006 and February 2010. We classified the patients into 7 groups: distal subungual onychomycosis (DSO) type I (~25% involved), type II (25~50%), type III (50~75%), type IV (75~100%), proximal subungual onychomycosis (PSO), superficial white onychomycosis (SWO), and candidal OM. The patients were treated with systemic agents including terbinafine, fluconazole and itraconazole. We analyzed the clinical data for factors affecting the duration of treatement and recurrence of onychomycosis. The factors included age, sex, subtype of onychomycosis, type of systemic antifungal agent as well as the existence of comorbidities. Results: A total of 227 patients were enrolled: their mean age was 56.9 years (range, 11~90); mean duration of treatment was 7.2 months (range, 1~24). The duration of treatment of DSO type I (6.2months) was shorter than that of DSO III (8.5 months) and IV (9.0 months). The other factors including age, sex, the existence of diabetes or vascular disease, and the type of systemic agents did not affect the duration of treatment. The recurrence rates after successful treatment were 12.5% in the patients with diabetes and 2.6% in the patients without diabetes (p = 0.026). There was no difference in recurrence rates of the patients with or without vascular diseases. Conclusion: The duration of treatment to cure OM increased with the degree of involvement of DSO. No other factors affected the treatment duration significantly. recurrence rate was significantly higher in patients with diabetes.
참고문헌 (19)
- Gupta AK, "Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients", J Am Acad Dermatol, 43, pp.244~248 (2000)
- Sigurgeirsson B, "Prevalence of onychomycosis in Iceland: a populationbased study", Acta Derm Venereol, 82, pp.467~469 (2002)
- Elewski BE, "Onychomycosis. Treatment, quality of life, and economic issues", Am J Clin Dermatol, 1, pp.19~26 (2000)
- Cathcart S, "Onychomycosis and diabetes", J Eur Acad Dermatol Venereol, 23, pp.F1119~1122 (2009)
- Sigurgeirsson B, "Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective followup study", Arch Dermatol, 138, pp.353~357 (2002)
- Niewerth M, "Management of onychomycoses", Drugs, 58, pp.283~296 (1999)
- 강명승, "발톱진균증의 침범 정도에 따른 완치율과 정상화까지의 기간 및 재발률", 대한의진균학회지, 13(2), pp.53~60 (2008), 대한의진균학회1
- 김덕한, "조갑진균증의 임상적 고찰 : 조갑진균증의 치료에 영향을 주는 인자와 그에 따른 치유율 비교", 대한의진균학회지, 10(2), pp.55~69 (2005), 대한의진균학회1
- Elewski BE, "Onychomycosis: pathogenesis, diagnosis, and management", Clin Microbiol Rev, 11, pp.415~429 (1998)
- 원종현, "발톱 조갑 진균증에서 Itraconazole 주기 요법과 Terbinafine 연속 요법의치료 효과에 대한 비교 연구- 96주간의 관찰", 대한의진균학회지, 12(3), pp.139~147 (2007), 대한의진균학회1
- Sommer S, "Prediction of outcome in the treatment of onychomycosis", Clin Exp Dermatol, 28, pp.425~428 (2003)
- Sigurgeirsson B, "Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents", Br J Dermatol, 147, pp.1241~1243 (2002)
- Yu HJ, "Is slow nail growth a risk factor for onychomycosis", Clin Exp Dermatol, 29, pp.415~418 (2004)
- Levy LA, "Epidemiology of onychomycosis in special-risk populations", J Am Podiatr Med Assoc, 87, pp.546~550 (1997)
- Heikkila H, "The prevalence of onychomycosis in Finland", Br J Dermatol, 133, pp.699~703 (1995)
- Sigurgeirsson B, "Prognostic factors for cure following treatment of onychomycosis", J Eur Acad Dermatol Venereol, 24, pp.679~684 (2010)
- Baran R, "Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals", Acta Derm Venereol, 76, pp.82~83 (1996)
- Gupta AK, "Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey", Br J Dermatol, 139, pp.665~671 (1998)
- Arca E, "An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis", J Dermatolog Treat, 13, pp.3~9 (2002)